Huvepharma acquires OptiPhos
Huvepharma and Enzyvia LLC announced that Huvepharma has acquired the global rights for the full OptiPhos brand, product and registrations from Enzyvia LLC.
OptiPhos is an E. coli 6-phytase, first marketed in 2006 in the United States and now sold in 47 countries around the world. Its is an efficient and stable phytase available in the market.
The addition of the global rights of OptiPhos is an extension to Huvepharma’s existing enzyme business. Huvepharma has previously marketed and distributed OptiPhos as a partner of Enzyvia LLC for different countries in the Middle East, Europe, Africa and Asia.
Along with the OptiPhos brand, all related patents, intellectual property, trademarks, global regulatory registrations, and production assets are included in this transaction. This acquisition gives Huvepharma a global position with the Optiphos current product range, concentrations, and services offered now for OptiPhos by Enzyvia LLC. This will be continued by Huvepharma during the transition and beyond.
“With this acquisition, Huvepharma has realised an integrated global sales, marketing and production organization for its leading phytase and xylanase brands. These brands are sold under the Optiphos and Hostazym brands around the world,”says Ir. Karel Bierman, Global product manager enzymes for Huvepharma.
